Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase IIa Study of the Safety and Clinical Proof-of-concept of NC-503 (Eprodisate Disodium) in Patients With Type II Diabetes and Features of Metabolic Syndrome

NCT00675857 is registered in ClinicalTrials.gov with Bellus Health Inc. - a GSK company as lead sponsor.

NCT NCT00675857
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00675857 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase IIa Study of the Safety and Clinical Proof-of-concept of NC-503 (Eprodisate Disodium) in Patients With Type II Diabetes and Features of Metabolic Syndrome
Lead sponsor
Bellus Health Inc. - a GSK company
Phase
Phase 2
Overall status
Completed
Start date
April 30, 2008
Completion date
May 31, 2010
Enrollment
200 (estimated)
Sites
21

Conditions

As the registry lists them; a condition with its own page is linked.

diabetes mellitus, type 2, metabolic syndrome x